A cost and time effective blood test to detect multiple bloodborne diseases

Informations projet

Safe-Blood

N° de convention de subvention: 826934

DOI

10.3030/826934

Projet clôturé

Date de signature de la CE 10 Août 2018

Date de début 1 Septembre 2018

Date de fin 28 Février 2019

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

WAMA DIAGNOSTICS (SWITZERLAND) SA
Switzerland

Periodic Reporting for period 1 - Safe-Blood (A cost and time effective blood test to detect multiple bloodborne diseases)

Période du rapport: 2018-09-01 au 2019-02-28

Résumé du contexte et des objectifs généraux du projet

Blood donations save many lives, but it is crucial to ensure safety of blood products prior to transfusion. The increasing demand of donor blood and ongoing worldwide emergence of new pathogens and variants will pose a tremendous burden on blood banks in the near future. These services make the blood screening analysis with separate tests (one test for one disease). Therefore, a streamlined method would help Blood Banks to attend this increasing demand.

WAMA has demonstrated the feasibility of Safe-Blood, a multiplex serological test that can detect up to six known pathogens in blood. Safe-Blood is the first multiplex test that will be offered to the blood screening market and will increase the efficiency, as well as cost-effectiveness, of the routine workflow of blood donation screening.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

To assess the commercial attractiveness of Safe-Blood, WAMA Diagnostics performed an in-depth market analysis to understand the main players and the tendencies of blood banks, researched the needs and demands of large European blood banks regarding blood screening though interviews, and identified potential threats to its technology.

In order to progress its business in the European market, WAMA Diagnostics also defined an intellectual property management strategy and identified potential future partners to develop the equipment necessary for the Safe-Blood test.

The technological feasibility assessment showed that, for the short-term progress of the project, WAMA shall partner with a large, experienced company with an established presence in the European market.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

WAMA developed and demonstrated the feasibility of the Safe-Blood test with a prototype for multiplex Chemiluminescence Immunoassay (CLIA) that is able to simultaneously detect six pathogens through 11 markers.

Information obtained in this project shows that the European blood screening market is moderately saturated with large, well-established companies supplying serological test to public and private blood organizations. However, serological testing is performed by using different test assays for each pathogen, instead of using one test for all screened disease. In this regard, Safe-Blood will clearly be a significant improvement for the routine workflows of blood banks because it will reduce hands-on time and overall expenses of using multiple systems.

The SAFE BLOOD test screens up to 6 bloodborne pathogens simultaneously in one well.